Prostatype Genomics Revenue vs. Current Valuation

PROGEN Stock  SEK 11.30  0.50  4.63%   
Based on Prostatype Genomics' profitability indicators, Prostatype Genomics AB may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Prostatype Genomics' ability to earn profits and add value for shareholders.
For Prostatype Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Prostatype Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Prostatype Genomics AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Prostatype Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Prostatype Genomics AB over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
Please note, there is a significant difference between Prostatype Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prostatype Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prostatype Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Prostatype Genomics Current Valuation vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Prostatype Genomics's current stock value. Our valuation model uses many indicators to compare Prostatype Genomics value to that of its competitors to determine the firm's financial worth.
Prostatype Genomics AB is rated top company in revenue category among its peers. It also is rated top company in current valuation category among its peers reporting about  2,062  of Current Valuation per Revenue. Comparative valuation analysis is a catch-all model that can be used if you cannot value Prostatype Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Prostatype Genomics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Prostatype Revenue vs. Competition

Prostatype Genomics AB is rated top company in revenue category among its peers. Market size based on revenue of Diagnostics & Research industry is at this time estimated at about 873.4 Million. Prostatype Genomics adds roughly 10,001 in revenue claiming only tiny portion of equities under Diagnostics & Research industry.

Prostatype Current Valuation vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Prostatype Genomics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
10 K
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Prostatype Genomics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
20.62 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Prostatype Current Valuation vs Competition

Prostatype Genomics AB is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Diagnostics & Research industry is at this time estimated at about 17.22 Billion. Prostatype Genomics adds roughly 20.62 Million in current valuation claiming only tiny portion of equities under Diagnostics & Research industry.

Prostatype Genomics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Prostatype Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Prostatype Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Prostatype Genomics' change in net profit over the period of time. It can combine multiple indicators of Prostatype Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. The company was founded in 2007 and is based in Solna, Sweden. Prostatype Genomics is traded on Stockholm Stock Exchange in Sweden.

Prostatype Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Prostatype Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Prostatype Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Prostatype Genomics' important profitability drivers and their relationship over time.

Use Prostatype Genomics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Prostatype Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Prostatype Genomics will appreciate offsetting losses from the drop in the long position's value.

Prostatype Genomics Pair Trading

Prostatype Genomics AB Pair Trading Analysis

The ability to find closely correlated positions to Prostatype Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Prostatype Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Prostatype Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Prostatype Genomics AB to buy it.
The correlation of Prostatype Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Prostatype Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Prostatype Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Prostatype Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Prostatype Genomics position

In addition to having Prostatype Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cars Thematic Idea Now

Cars
Cars Theme
Domestic and international companies involved in manufacturing and serving automobiles and trucks. The Cars theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cars Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Prostatype Stock

To fully project Prostatype Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Prostatype Genomics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Prostatype Genomics' income statement, its balance sheet, and the statement of cash flows.
Potential Prostatype Genomics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Prostatype Genomics investors may work on each financial statement separately, they are all related. The changes in Prostatype Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Prostatype Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.